Full Press Release Details
Media
• January 8, 2024
IRWD Positive Sentiment
Ironwood Pharmaceuticals Maintains FY 2023 Financial Guidance and Announces FY 2024 Financial Guidance
Key Takeaway: Ironwood Pharmaceuticals has confirmed its financial guidance for the fiscal year 2023 while also announcing its financial guidance for fiscal year 2024. This move reflects the company's confidence in its ongoing operations and future prospects. The announcement was made on January 8, 2024, highlighting the company's strategic planning.
Price reaction · baseline $12.45 (2024-01-05 close) · 1 other IRWD headline(s) in the window, move may be shared
day 0 close
+2.5%
Market Sentiment Analysis
POSITIVE FACTORS
- Ironwood Pharmaceuticals is maintaining its financial guidance for FY 2023.
- The company has announced financial guidance for FY 2024.
- Positive outlook may indicate stability and confidence in future performance.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+57%
120-day peak, hindsight
Typical move
3.8%
average across 2 past catalysts
Lead asset
IW-3718
Phase 3 · Gastroesophageal Reflux Disease (GERD)
Frequently Asked Questions
What financial guidance did Ironwood announce for FY 2024?
Ironwood Pharmaceuticals announced its financial guidance for FY 2024.
Is Ironwood maintaining its FY 2023 financial guidance?
Yes, Ironwood Pharmaceuticals is maintaining its financial guidance for FY 2023.
When was the financial guidance announcement made?
The announcement was made on January 8, 2024.